New study validates clotting risk factors in chronic kidney disease

January 17, 2018

(Boston)--In late 2017, researchers from Boston University School of Medicine (BUSM) discovered and published (Science Translational Medicine, (9) 417, Nov 2017) a potential treatment target to prevent chronic kidney disease (CKD) patients from developing thrombosis (blood clots) without causing bleeding complications. They found that boosting a regulatory protein named STUB1 decreased the abundance of tissue factor (TF) and prevented blood vessel blockages in experimental models.

Now, these same researchers have tested other aspect of this hypothesis in humans with promising results. Chronic kidney disease is associated with buildup of urea in the blood, and leads to accumulation of "uremic" solutes, which was thought to result in cardiovascular toxicity including thrombosis.

Led by BUSM senior author and senior co-author, Vipul Chitalia, MD, PhD, associate professor of medicine, and Katya Ravid, DSc, professor of medicine and biochemistry, an interdisciplinary team expanded their previous study using two independent human cohorts in which blood plasma was analyzed for uremic solutes that are tryptophan byproducts such as indoxyl sulfate (IS) and TF activity, among other tests. Tryptophan is an essential amino acid, meaning the body cannot synthesize it, and must be obtained from the diet.

Using cutting edge machine learning approaches, the researchers analyzed samples from 473 participants of the Dialysis Access Consortium Clopidogrel Prevention of Early AV Fistula Thrombosis trial with advanced CKD, as well as 377 baseline samples from participants in the Thrombolysis in Myocardial Infarction II trial, many of whom had CKD stage 2-3. "Both groups showed an association between blood clotting and the level of IS as well as TF activity. They also found another association between patients who had clots with higher levels of kynurenine, which is another uremic solute found in patients who developed blood clots in surgically created passageways between an artery and a vein, known as arteriovenous fistula," explained Chitalia. Overall, this work confirms the effects of uremic solutes in humans and shows that a set of uremic solutes strongly influences thrombosis in patients with different levels of kidney function.

"The translation of findings from experimental models to humans can be challenging. However, this human validation of tryptophan metabolites-TF axis supports further studies probing its utility in risk stratification of CKD patients and exploring its role in other diseases with heightened risk of thrombosis." said Ravid.
-end-
The study, with Vijaya B. Kolachalama, PhD, assistant professor of medicine, as first author and collaborators such as Anqi Zhang, PhD, instructor of medicine, Jean Francis, MD, assistant professor of medicine and Laura M. Dember, MD, professor of medicine, was published in the Journal of American Society of Nephrology (a top tier journal in the field of renal diseases) and supported by National Institute of Health grants to Chitalia and Ravid and by the Evans Center for Interdisciplinary Biomedical Research ARC on Thrombosis.

Boston University School of Medicine

Related Blood Clots Articles from Brightsurf:

New cause of COVID-19 blood clots identified
A new study reveals that COVID-19 triggers production of antibodies circulating through the blood, causing clots in people hospitalized with the disease.

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

COVID-19 may cause deadly blood clots
COVID-19 may increase the risk of blot cots in women who are pregnant or taking estrogen with birth control or hormone replacement therapy, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

New evidence for how blood clots may form in very ill COVID-19 patients
Neutrophil Extracellular Traps (NETs) have been implicated in causing excessive clotting in cancer patients.

Researchers find new way to detect blood clots
Researchers in the Department of Biomedical Engineering at Texas A&M University are working on an entirely new way to detect blood clots, especially in pediatric patients.

High rate of blood clots in COVID-19
COVID-19 is associated with a high incidence of venous thromboembolism, blood clots in the venous circulation, according to a study conducted by researchers at Brighton and Sussex Medical School (BSMS), UK.

New tool helps distinguish the cause of blood clots
A new tool using cutting-edge technology is able to distinguish different types of blood clots based on what caused them, according to a study published today in eLife.

Hookah smoke may be associated with increased risk of blood clots
In a new study conducted in mice, researchers found that tobacco smoke from a hookah caused blood to function abnormally and be more likely to clot and quickly form blood clots.

Reducing the risk of blood clots in artificial heart valves
People with mechanical heart valves need blood thinners on a daily basis, because they have a higher risk of blood clots and stroke.

New study provides insight into the mechanisms of blood clots in cancer patients
Researchers have identified a potential new signaling pathway that may help further the understanding of blood clot formation in cancer patients and ultimately help prevent this complication from occurring.

Read More: Blood Clots News and Blood Clots Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.